NCT05321706 - DAPAgliflozin for Renal Protection in Heart Transplant Recipients | Biotech Hunter

Enrollment

430

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

May 31, 2028

Conditions

Heart Transplant FailureKidney Failure

Interventions

DRUG

Dapagliflozin 10 mg

Participants will be randomized in a 1:1 fashion to receive 10 mg of oral dapagliflozin

DRUG

Placebo

Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.

Trial Locations (6)

NOT_YET_RECRUITING

Skane University Hospital, Lund

RECRUITING

University Medical Center Groningen, Groningen

RECRUITING

Erasmus Medical Center, Rotterdam

NOT_YET_RECRUITING

Karolinska University Hospital, Stockholm

RECRUITING

Oslo University Hospital, Rikshospitalet, Oslo

NOT_YET_RECRUITING

Sahlgrenska University Hospital, Gothenburg